Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1023 participants.

Also called NCT03112707

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,023 participants (planned count) (from the registry)
Sponsor
Humanitas Hospital, Italy (from the registry)
Registry
  • NCT NCT03112707
Other papers using this trial's data
  • Early oral anticoagulation monotherapy after PCI: Insights from the POEM trial American heart journal, 2026-03 DOI, PubMed 41271123

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT03112707. Allocation not applicable; no masking; primary purpose treatment. Start 2017-04-14 (actual); primary completion 2020-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT
Acronym
POEM
Condition
Acute Coronary Syndrome
Intervention (Drug)
Aspirin
Intervention (Drug)
P2Y12 inhibitor
Lead sponsor
Humanitas Hospital, Italy (class: other)

Record details

Record id
cardio:ct-nct03112707
Content hash
861928fdd32f596bac3cde9da1ea1a5e5d766fa7b6f394192f632a91fb3c125b